 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Phase I Systemic Delivery Trial - United States In June 2007, Oncolytics announced positive results from its Phase I clinical trial to investigate the systemic delivery of REOLYSIN® as a treatment for patients with advanced or metastatic solid tumours. Of the 18 patients treated, eight demonstrated stable disease as measured by RECIST (Response Evaluation Criteria in Solid Tumours) including a patient with progressive breast cancer who experienced a 28.5% shrinkage in tumour volume. The primary objective of the study is to determine the maximum tolerated dose, dose limiting toxicity and safety profile of REOLYSIN®. Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumour activity. See related press releases: June 5, 2007 - Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN® Trial August 23, 2006 - Oncolytics Biotech Inc. Completes Patient Enrolment in U.S. Phase I Systemic Administration Clinical Trial September 28, 2005 - Oncolytics Biotech Inc. Begins Patient Enrolment in U.S. Systemic Delivery Clinical Trial April 7, 2005 - Oncolytics Biotech Inc. Receives FDA Clearance to Initiate Phase I Systemic Delivery Clinical Trial
|
|
|||||||||||
 |
|
 |